| __timestamp | Amphastar Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 60987000 |
| Thursday, January 1, 2015 | 174172000 | 125542000 |
| Friday, January 1, 2016 | 150976000 | 210460000 |
| Sunday, January 1, 2017 | 149380000 | 275119000 |
| Monday, January 1, 2018 | 187681000 | 409539000 |
| Tuesday, January 1, 2019 | 190434000 | 547758000 |
| Wednesday, January 1, 2020 | 206506000 | 736300000 |
| Friday, January 1, 2021 | 238029000 | 904200000 |
| Saturday, January 1, 2022 | 250127000 | 1080300000 |
| Sunday, January 1, 2023 | 293274000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Vertex Pharmaceuticals Incorporated and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Vertex Pharmaceuticals has seen a staggering increase in its cost of revenue, growing by over 1,900%, from approximately $61 million in 2014 to $1.26 billion in 2023. This reflects Vertex's aggressive expansion and investment in research and development. In contrast, Amphastar Pharmaceuticals experienced a more modest growth of around 84%, with costs rising from $159 million to $293 million. This steady increase highlights Amphastar's consistent operational strategy. The data underscores the contrasting growth trajectories and strategic priorities of these two pharmaceutical giants, offering valuable insights for market analysts and investors.
Analyzing Cost of Revenue: Johnson & Johnson and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs MorphoSys AG
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Vericel Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated or Amphastar Pharmaceuticals, Inc.: Who Leads in Yearly Revenue?
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses